Extracorporeal photopheresis for the treatment of steroid refractory acute GVHD

P. Perfetti, P. Carlier, P. Strada, F. Gualandi, D. Occhini, M. T. Van Lint, A. Ibatici, T. Lamparelli, B. Bruno, A. M. Raiola, A. Dominietto, C. Di Grazia, S. Bregante, S. Zia, G. M. Ferrari, P. Stura, E. Pogliani, A. Bacigalupo

Research output: Contribution to journalArticle

84 Citations (Scopus)

Abstract

Extracorporeal photopheresis (ECP) was given to 23 patients with steroid-refractory acute GVHD (aGVHD, grade II (n=10), III (n=7) or IV (n=6)). The median duration of ECP was 7 months (1-33) and the median number of ECP cycles in each patient was 10. Twelve patients (52%) had complete responses. Eleven patients (48%) survived and 12 died, 10 of GVHD with or without infections and two of leukaemia relapse. The average grade of GVHD was reduced from 2.8 (on the first day of ECP) to 1.4 (on day +90 from ECP) (P=0.08), and the average dose of i.v. methylprednisolone from 2.17 to 0.2mg/kg/d (P=0.004). Complete responses were obtained in 70, 42 and 0% of patients, respectively, with grades II, III and IV aGVHD; complete responses in the skin, liver and gut were 66, 27 and 40%. Patients treated within 35 days from onset of aGVHD had higher responses (83 vs 47%; P=0.1). A trend for improved survival was seen in grade III-IV aGVHD treated with ECP as compared to matched controls (38 vs 16%; P 0.08). ECP is a treatment option for patients with steroid refractory aGVHD and should be considered early in the course of the disease.

Original languageEnglish
Pages (from-to)609-617
Number of pages9
JournalBone Marrow Transplantation
Volume42
Issue number9
DOIs
Publication statusPublished - 2008

Fingerprint

Photopheresis
Steroids
Therapeutics
Methylprednisolone
Leukemia
Recurrence
Skin
Survival
Liver

ASJC Scopus subject areas

  • Hematology
  • Transplantation

Cite this

Extracorporeal photopheresis for the treatment of steroid refractory acute GVHD. / Perfetti, P.; Carlier, P.; Strada, P.; Gualandi, F.; Occhini, D.; Van Lint, M. T.; Ibatici, A.; Lamparelli, T.; Bruno, B.; Raiola, A. M.; Dominietto, A.; Di Grazia, C.; Bregante, S.; Zia, S.; Ferrari, G. M.; Stura, P.; Pogliani, E.; Bacigalupo, A.

In: Bone Marrow Transplantation, Vol. 42, No. 9, 2008, p. 609-617.

Research output: Contribution to journalArticle

Perfetti, P, Carlier, P, Strada, P, Gualandi, F, Occhini, D, Van Lint, MT, Ibatici, A, Lamparelli, T, Bruno, B, Raiola, AM, Dominietto, A, Di Grazia, C, Bregante, S, Zia, S, Ferrari, GM, Stura, P, Pogliani, E & Bacigalupo, A 2008, 'Extracorporeal photopheresis for the treatment of steroid refractory acute GVHD', Bone Marrow Transplantation, vol. 42, no. 9, pp. 609-617. https://doi.org/10.1038/bmt.2008.221
Perfetti, P. ; Carlier, P. ; Strada, P. ; Gualandi, F. ; Occhini, D. ; Van Lint, M. T. ; Ibatici, A. ; Lamparelli, T. ; Bruno, B. ; Raiola, A. M. ; Dominietto, A. ; Di Grazia, C. ; Bregante, S. ; Zia, S. ; Ferrari, G. M. ; Stura, P. ; Pogliani, E. ; Bacigalupo, A. / Extracorporeal photopheresis for the treatment of steroid refractory acute GVHD. In: Bone Marrow Transplantation. 2008 ; Vol. 42, No. 9. pp. 609-617.
@article{35a25d609e2b4ac8a24eba1b1368a661,
title = "Extracorporeal photopheresis for the treatment of steroid refractory acute GVHD",
abstract = "Extracorporeal photopheresis (ECP) was given to 23 patients with steroid-refractory acute GVHD (aGVHD, grade II (n=10), III (n=7) or IV (n=6)). The median duration of ECP was 7 months (1-33) and the median number of ECP cycles in each patient was 10. Twelve patients (52{\%}) had complete responses. Eleven patients (48{\%}) survived and 12 died, 10 of GVHD with or without infections and two of leukaemia relapse. The average grade of GVHD was reduced from 2.8 (on the first day of ECP) to 1.4 (on day +90 from ECP) (P=0.08), and the average dose of i.v. methylprednisolone from 2.17 to 0.2mg/kg/d (P=0.004). Complete responses were obtained in 70, 42 and 0{\%} of patients, respectively, with grades II, III and IV aGVHD; complete responses in the skin, liver and gut were 66, 27 and 40{\%}. Patients treated within 35 days from onset of aGVHD had higher responses (83 vs 47{\%}; P=0.1). A trend for improved survival was seen in grade III-IV aGVHD treated with ECP as compared to matched controls (38 vs 16{\%}; P 0.08). ECP is a treatment option for patients with steroid refractory aGVHD and should be considered early in the course of the disease.",
author = "P. Perfetti and P. Carlier and P. Strada and F. Gualandi and D. Occhini and {Van Lint}, {M. T.} and A. Ibatici and T. Lamparelli and B. Bruno and Raiola, {A. M.} and A. Dominietto and {Di Grazia}, C. and S. Bregante and S. Zia and Ferrari, {G. M.} and P. Stura and E. Pogliani and A. Bacigalupo",
year = "2008",
doi = "10.1038/bmt.2008.221",
language = "English",
volume = "42",
pages = "609--617",
journal = "Bone Marrow Transplantation",
issn = "0268-3369",
publisher = "Nature Publishing Group",
number = "9",

}

TY - JOUR

T1 - Extracorporeal photopheresis for the treatment of steroid refractory acute GVHD

AU - Perfetti, P.

AU - Carlier, P.

AU - Strada, P.

AU - Gualandi, F.

AU - Occhini, D.

AU - Van Lint, M. T.

AU - Ibatici, A.

AU - Lamparelli, T.

AU - Bruno, B.

AU - Raiola, A. M.

AU - Dominietto, A.

AU - Di Grazia, C.

AU - Bregante, S.

AU - Zia, S.

AU - Ferrari, G. M.

AU - Stura, P.

AU - Pogliani, E.

AU - Bacigalupo, A.

PY - 2008

Y1 - 2008

N2 - Extracorporeal photopheresis (ECP) was given to 23 patients with steroid-refractory acute GVHD (aGVHD, grade II (n=10), III (n=7) or IV (n=6)). The median duration of ECP was 7 months (1-33) and the median number of ECP cycles in each patient was 10. Twelve patients (52%) had complete responses. Eleven patients (48%) survived and 12 died, 10 of GVHD with or without infections and two of leukaemia relapse. The average grade of GVHD was reduced from 2.8 (on the first day of ECP) to 1.4 (on day +90 from ECP) (P=0.08), and the average dose of i.v. methylprednisolone from 2.17 to 0.2mg/kg/d (P=0.004). Complete responses were obtained in 70, 42 and 0% of patients, respectively, with grades II, III and IV aGVHD; complete responses in the skin, liver and gut were 66, 27 and 40%. Patients treated within 35 days from onset of aGVHD had higher responses (83 vs 47%; P=0.1). A trend for improved survival was seen in grade III-IV aGVHD treated with ECP as compared to matched controls (38 vs 16%; P 0.08). ECP is a treatment option for patients with steroid refractory aGVHD and should be considered early in the course of the disease.

AB - Extracorporeal photopheresis (ECP) was given to 23 patients with steroid-refractory acute GVHD (aGVHD, grade II (n=10), III (n=7) or IV (n=6)). The median duration of ECP was 7 months (1-33) and the median number of ECP cycles in each patient was 10. Twelve patients (52%) had complete responses. Eleven patients (48%) survived and 12 died, 10 of GVHD with or without infections and two of leukaemia relapse. The average grade of GVHD was reduced from 2.8 (on the first day of ECP) to 1.4 (on day +90 from ECP) (P=0.08), and the average dose of i.v. methylprednisolone from 2.17 to 0.2mg/kg/d (P=0.004). Complete responses were obtained in 70, 42 and 0% of patients, respectively, with grades II, III and IV aGVHD; complete responses in the skin, liver and gut were 66, 27 and 40%. Patients treated within 35 days from onset of aGVHD had higher responses (83 vs 47%; P=0.1). A trend for improved survival was seen in grade III-IV aGVHD treated with ECP as compared to matched controls (38 vs 16%; P 0.08). ECP is a treatment option for patients with steroid refractory aGVHD and should be considered early in the course of the disease.

UR - http://www.scopus.com/inward/record.url?scp=56349140988&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=56349140988&partnerID=8YFLogxK

U2 - 10.1038/bmt.2008.221

DO - 10.1038/bmt.2008.221

M3 - Article

C2 - 18660840

AN - SCOPUS:56349140988

VL - 42

SP - 609

EP - 617

JO - Bone Marrow Transplantation

JF - Bone Marrow Transplantation

SN - 0268-3369

IS - 9

ER -